Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy
Case reports have documented Lactobacillus bacteremia and Saccharomyces fungemia in vulnerable populations, with the latter particularly associated with central venous catheter use, though incidence remains extremely low
The examples in this article are illustrative, not treatment plans
Because users vary in how they describe their symptoms, the effort required to map individual social media posts to language in the Medical Dictionary for Regulatory Activities (MedDRA), which clinicians use to describe symptoms, limited the amount of data this approach could handle
The Human Side of the GLP-1 Divide Numbers only tell part of the story
Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I